JCEM:重症患者的高热量暴露会加速甲状腺激素的活化

2019-10-05 xing.T MedSci原创

由此可见,NTIS患者较高的热量暴露会暂时减缓血浆T3/rT3比值的下降,接下来3天较高的热量暴露会使这种作用最小化并最终消失。

严重疾病的炎症反应伴有非甲状腺疾病综合症(NTIS)。有研究证实进食可减轻这一过程,但尚未对重症患者随时间进行前瞻性研究。近日,内分泌和代谢性疾病领域权威杂志Journal of Clinical Endocrinology & Metabolism上发表了一篇研究文章,该研究探讨重症患者随时间变化的卡路里摄入量对NTIS的影响。


机械通气的全身性炎症反应综合征(SIRS)患者随机接受其估计热量需求的100%或40%(分别为100%ECN和40%ECN)。每天测量甲状腺激素,持续7天,或直到重症监护病房患者出院或死亡。研究人员采用混合水平回归模型探究了随机分组对血浆T3/rT3比率以及T3、rT3、T4和TSH的影响。


有35名参与者(100%ECN中的19名,40%ECN中的16名)被纳入研究。调整基线T3/rT3比值的组间差异后,定义拟合曲线的参数(截距、研究日的线性效应和研究日的二次效应)因随机分组而有所不同(分别为p=0.001、p=0.01和p=0.02)。拟合曲线图显示,干预后第1天与40%ECN组相比,干预后第1天100%ECN组的参与者的T3/rT3比值高出54%,随着时间的推移,差异有所减弱。这是由于干预后1天血浆T3升高23%,血浆rT3降低10%。


由此可见,NTIS患者较高的热量暴露会暂时减缓血浆T3/rT3比值的下降,接下来3天较高的热量暴露会使这种作用最小化并最终消失。 


原始出处:


Liam McKeever,et al.Higher caloric exposure in critically ill patients transiently accelerates thyroid hormone activation.J Clin Endocrinol Metab. 2019.https://doi.org/10.1210/clinem/dgz077


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1822308, encodeId=68e3182230818, content=<a href='/topic/show?id=0261102508a3' target=_blank style='color:#2F92EE;'>#高热量暴露#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102508, encryptionId=0261102508a3, topicName=高热量暴露)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ba7103, createdName=xuqianhua, createdTime=Thu Oct 17 06:21:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063271, encodeId=281220632e13c, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Mon Mar 09 13:21:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777889, encodeId=1f171e77889bf, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Mon May 18 05:21:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284070, encodeId=d8ef12840e029, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Mon Oct 07 00:21:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613862, encodeId=d447161386277, content=<a href='/topic/show?id=d87e6e25687' target=_blank style='color:#2F92EE;'>#热量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67256, encryptionId=d87e6e25687, topicName=热量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bba919440409, createdName=ms2536978994064944, createdTime=Mon Oct 07 00:21:00 CST 2019, time=2019-10-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1822308, encodeId=68e3182230818, content=<a href='/topic/show?id=0261102508a3' target=_blank style='color:#2F92EE;'>#高热量暴露#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102508, encryptionId=0261102508a3, topicName=高热量暴露)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ba7103, createdName=xuqianhua, createdTime=Thu Oct 17 06:21:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063271, encodeId=281220632e13c, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Mon Mar 09 13:21:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777889, encodeId=1f171e77889bf, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Mon May 18 05:21:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284070, encodeId=d8ef12840e029, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Mon Oct 07 00:21:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613862, encodeId=d447161386277, content=<a href='/topic/show?id=d87e6e25687' target=_blank style='color:#2F92EE;'>#热量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67256, encryptionId=d87e6e25687, topicName=热量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bba919440409, createdName=ms2536978994064944, createdTime=Mon Oct 07 00:21:00 CST 2019, time=2019-10-07, status=1, ipAttribution=)]
    2020-03-09 achengzhao
  3. [GetPortalCommentsPageByObjectIdResponse(id=1822308, encodeId=68e3182230818, content=<a href='/topic/show?id=0261102508a3' target=_blank style='color:#2F92EE;'>#高热量暴露#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102508, encryptionId=0261102508a3, topicName=高热量暴露)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ba7103, createdName=xuqianhua, createdTime=Thu Oct 17 06:21:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063271, encodeId=281220632e13c, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Mon Mar 09 13:21:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777889, encodeId=1f171e77889bf, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Mon May 18 05:21:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284070, encodeId=d8ef12840e029, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Mon Oct 07 00:21:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613862, encodeId=d447161386277, content=<a href='/topic/show?id=d87e6e25687' target=_blank style='color:#2F92EE;'>#热量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67256, encryptionId=d87e6e25687, topicName=热量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bba919440409, createdName=ms2536978994064944, createdTime=Mon Oct 07 00:21:00 CST 2019, time=2019-10-07, status=1, ipAttribution=)]
    2020-05-18 smallant2015
  4. [GetPortalCommentsPageByObjectIdResponse(id=1822308, encodeId=68e3182230818, content=<a href='/topic/show?id=0261102508a3' target=_blank style='color:#2F92EE;'>#高热量暴露#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102508, encryptionId=0261102508a3, topicName=高热量暴露)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ba7103, createdName=xuqianhua, createdTime=Thu Oct 17 06:21:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063271, encodeId=281220632e13c, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Mon Mar 09 13:21:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777889, encodeId=1f171e77889bf, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Mon May 18 05:21:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284070, encodeId=d8ef12840e029, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Mon Oct 07 00:21:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613862, encodeId=d447161386277, content=<a href='/topic/show?id=d87e6e25687' target=_blank style='color:#2F92EE;'>#热量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67256, encryptionId=d87e6e25687, topicName=热量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bba919440409, createdName=ms2536978994064944, createdTime=Mon Oct 07 00:21:00 CST 2019, time=2019-10-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1822308, encodeId=68e3182230818, content=<a href='/topic/show?id=0261102508a3' target=_blank style='color:#2F92EE;'>#高热量暴露#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102508, encryptionId=0261102508a3, topicName=高热量暴露)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ba7103, createdName=xuqianhua, createdTime=Thu Oct 17 06:21:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063271, encodeId=281220632e13c, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Mon Mar 09 13:21:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777889, encodeId=1f171e77889bf, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Mon May 18 05:21:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284070, encodeId=d8ef12840e029, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Mon Oct 07 00:21:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613862, encodeId=d447161386277, content=<a href='/topic/show?id=d87e6e25687' target=_blank style='color:#2F92EE;'>#热量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67256, encryptionId=d87e6e25687, topicName=热量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bba919440409, createdName=ms2536978994064944, createdTime=Mon Oct 07 00:21:00 CST 2019, time=2019-10-07, status=1, ipAttribution=)]

相关资讯

近期批准和高级研发用以治疗重症患者的抗生素前景和困境

简介 抗生素耐药的逐渐增加是重症患者的一个主要问题,直接导致这些患者住院时间延长和死亡率增加。在这种情况下,对降低死亡率和改善临床结果至关重要的适当抗生素处方常被延误,最常用的经验性抗生素治疗方案往往是不合适的。为了解决抗生素耐药问题,最近批准了许多具有抗多重耐药菌(MDR)的新抗生素,其他新药目前也正在研发中。在这里,我们综述了治疗MDR引起的严重感染新治疗方案的特点,特别关注这些药物

保证重症患者的生活质量:重症营养治疗

重症患者需要足够的营养支持,以满足其在ICU住院期间和出ICU之后的能量需求,以对抗严重的分解代谢并预防肌肉萎缩。ICU患者经常发展成为慢性重病(chronic critical illness)患者,导致能耗增加、蛋白质分解和肌肉丢失。适当的调整热量和蛋白质的摄入可以避免喂养不足或过度喂养,这两者都可能导致不良预后。间接量热法是评估静息能耗(resting energy expenditure,

2019 SFPT/SFAR指南:优化重症患者β-内酰胺类抗生素治疗

2019年3月,法国药理学和治疗学学会(SFPT)联合法国麻醉和重症医学学会(SFAR)就重症患者使用β-内酰胺类抗生素治疗的方案优化提出指导建议,β-内酰胺类抗生素史ICU内应用最广泛的抗生素,本文主要针对这类患者的优化治疗提供指导建议,共涉及四个领域的21项优化建议。

Crit Care Med:血必净注射液治疗社区获得性肺炎重症患者的疗效

由此可见,在社区获得性肺炎重症患者中,血必净注射液导致肺炎严重程度指数显著改善,并且死亡率、机械通气持续时间和ICU住院时间也显著改善。

Chest:循环线粒体DNA作为重症患者死亡率的预测因子

由此可见,人们越来越关注mtDNA作为重症患者死亡率的预测因子。大多数研究规模较少,缺乏验证队列,并利用不同的方案来测量mtDNA。AUROC分析通常表明mtDNA与死亡率之间存在统计学上的显著相关性。mtDNA方案的标准化和大型、前瞻性、多中心试验的完成可能有必要明确mtDNA的临床有用性。

Intens Care Med:协议化家庭支持干预减少重症患者ICU停留时间

由此可见,加强沟通和与家人共同决策的协议化家庭支持干预减少了重症患者ICU的LOS而不影响死亡率。